Summary
Schering-Plough Corporation faced a challenging year in 2004, marked by a significant net loss of $947 million. This downturn was largely attributed to the loss of market exclusivity for key products like CLARITIN and REBETOL, coupled with increased market competition and substantial special charges related to litigation and restructuring. Despite a slight decrease in overall net sales to $8.3 billion, the company saw growth in specific segments like Animal Health and Consumer Health Care, and notable international sales increases for REMICADE. The company is actively pursuing a turnaround strategy under new leadership, focusing on key growth drivers such as the cholesterol franchise (VYTORIN and ZETIA) developed in partnership with Merck, and is seeking to improve financial stability through various means, including the repatriation of foreign earnings under the American Jobs Creation Act of 2004.
Key Highlights
- 1Schering-Plough reported a significant net loss of $947 million for the year ended December 31, 2004, a sharp decline from the previous year's loss of $92 million and a stark contrast to the $1.97 billion profit in 2002.
- 2Consolidated net sales saw a slight decrease of 1% to $8.27 billion in 2004, primarily driven by volume declines in the Prescription Pharmaceuticals segment, although offset by favorable foreign exchange rates.
- 3The Prescription Pharmaceuticals segment experienced a 3% sales decline to $6.42 billion, heavily impacted by the loss of exclusivity and increased competition for products like REBETOL (down 55%) and PEG-INTRON (down 30%).
- 4Significant special charges of $153 million were recorded in 2004, primarily related to employee termination costs ($119 million), compared to $599 million in 2003 which included substantial litigation reserves.
- 5The company is strategically investing in its cholesterol franchise, VYTORIN and ZETIA, through a joint venture with Merck, which contributed $1.2 billion in global sales in 2004, showing strong growth and becoming a key focus for future revenue.
- 6Schering-Plough is addressing compliance issues, including an ongoing consent decree with the FDA related to manufacturing practices, which has led to increased operating costs and reduced output.
- 7The company's financial strategy includes repatriating approximately $9.4 billion of unremitted foreign earnings under the American Jobs Creation Act of 2004, aimed at enhancing financial stability and funding U.S. operations.